查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2007889

再生医学技术市场预测至2034年—按产品类型、原料、技术、应用、最终用户和地区分類的全球分析

Regenerative Medicine Technologies Market Forecasts to 2034 - Global Analysis By Product Type, Source, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2026 年，全球再生医学技术市场规模将达到 184 亿美元，并在预测期内以 19.8% 的复合年增长率增长，到 2034 年将达到 782 亿美元。

再生医学是指生物医学的一个交叉学科领域，它致力于利用生物体的修復和自我再生机制来修復、替换或再生受损的组织和器官。这包括干细胞疗法、基因治疗载体、组织工程构建体、生物材料支架和基于细胞的免疫疗法。这些技术利用自体、同种异体和异种细胞来源，并结合生物製程平台、3D生物列印系统和基于CRISPR的基因编辑工具，以治疗整形外科、心臟科、神经科、皮肤科和肿瘤科的疾病。

基因治疗的监管核准

基因疗法的监管核准正在加速再生医学市场的扩张。 FDA和EMA对治疗遗传疾病的里程碑式核准，证明了先进细胞和基因疗法的商业性和临床可行性。多种罕见疾病基因疗法的核准，树立了市场价格标桿，并表明了支付意愿，从而吸引了大量投资，推动更广泛的再生医学技术研发。在核准产品的支持下，产能的扩张进一步降低了单位成本，并使更多患者能够获得这项技术。

复杂的製造和规模化挑战

复杂的生物製造要求和规模化生产挑战是再生医学技术商业化面临的最重大营运障碍之一。自体细胞疗法的生产需要为每位患者量身定制个人化的生产过程，难以标准化，导致单次给药成本高昂，与更广泛的医疗保健系统的经济效益不符。虽然异体细胞平台的开发缓解了一些规模化生产的限制，但也引入了免疫抗原性管理的复杂性。细胞增殖、製剂配製和分销流程中的污染风险和无菌要求，需要投入大量资金以确保符合GMP规范。

整形外科再生医学的应用

再生医学在整形外科的应用大规模，因为它比目前的手术和药物疗法更能有效地应对全球老龄化人口中日益普遍的肌肉骨骼疾病。利用生物材料支架和生长因子递送平台进行软骨修復、骨再生和肌腱癒合的应用正在顺利推进监管核准流程。由于治疗成本和报销条件与现有标准治疗方法相当，骨科医生将再生医学辅助疗法纳入既定的商业性流程后，已初见成效。

与定价和还款永续性相关的挑战

定价和报销永续性的挑战对再生医学技术开发商构成系统性的商业性威胁。这是因为根治性疗法需要新的支付模式，而传统的年度保费或固定费率支付（空洞化）结构无法满足这些需求。儘管目前正与支付方积极就基于价值的支付框架、年金式报销方案和基于结果的支付机制进行谈判，但尚未建立标准化的实施框架。医疗技术评估机构对再生医学定价申请的审查极为严格，这延长了产品上市时间。

新冠疫情的影响：

新冠疫情扰乱了临床实验医学的临床试验计划，导致试验中心关闭、病患招募暂停，多个后期计画因此延期一至两年。然而，疫情期间对mRNA技术的投资加速了适用于再生医学基因治疗载体的递送平台的创新。疫情后，监管机构和生产商合作制定了临床试验韧性框架，从根本上改善了专案连续性规划。

在预测期内，脚手架技术领域预计将占据最大的市场份额。

由于组织工程在整形外科、创伤治疗和心臟修復等领域具有广泛的临床效用，以及相对成熟的生产製造和监管核准体系，预计支架技术领域将在预测期内占据最大的市场份额。水凝胶、生物陶瓷和可生物降解聚合物等生物相容性支架材料已在多个已通过核准的医疗设备产品中取得了商业性成功。 3D生物列印技术在支架设计中的日益普及，使得支架能够根据患者的特定解剖结构进行定制，从而拓展了其临床应用范围。

在预测期内，自体细胞细分市场预计将呈现最高的复合年增长率。

在预测期内，自体细胞疗法领域预计将呈现最高的成长率，这主要得益于CAR-T细胞疗法在骨髓恶性肿瘤治疗中市场渗透率的不断提高、自体软骨细胞移植术在软骨修復中的应用日益广泛以及自体干细胞移植在造血重建中的应用不断增长。自体细胞疗法的监管核准正在加速推进，多个处于III期临床试验阶段的项目已取得积极的疗效数据。由于对生产自动化的投资，自体细胞疗法的生产成本正在逐渐降低。

市占率最大的地区：

在整个预测期内，北美预计将保持最大的市场份额，这得益于其集中的已通过核准的细胞和基因治疗产品、一流的学术和医学研究基础设施，以及私人和政府对再生医学技术开发的大量投资。美国食品药物管理局（FDA）的生技药品评估和研究中心（CBER）已建立完善的监管流程，以支持细胞和基因疗法的商业化。包括百时美施贵宝和吉利德科学主要企业在CAR-T疗法市场保持主导地位。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率。促成这一增长的因素包括：日本创新性的「先岳」（SAKIGAKE）认定，该认定加速了再生医学的核准；韩国积极主动的细胞疗法法规结构；以及中国对国内干细胞疗法研发项目的巨额投资。亚太地区各国政府对国家再生医学中心的资助正在建立临床试验基础设施，这为全球技术合作创造了机会，并加速了该地区产品的上市。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，我们可以提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需要进行可行性测试）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章 全球再生医学技术市场：依产品类型划分

  • 干细胞疗法
  • 组织工程
  • 基因治疗
  • 生物材料
  • 鹰架技术
  • 细胞免疫疗法
  • 其他产品类型

第六章：全球再生医学技术市场：依来源划分

  • 自体细胞
  • 同种异体细胞
  • 外来细胞
  • 胚胎干细胞
  • 成体干细胞
  • 诱导性多功能干细胞
  • 其他来源

第七章 全球再生医学技术市场：依技术划分

  • 3D生物列印
  • CRISPR基因编辑
  • 细胞再程式化
  • 奈米科技
  • 生物製程技术
  • 生物反应器

第八章 全球再生医学技术市场：依应用划分

  • 整形外科
  • 循环系统
  • 神经病学
  • 皮肤科
  • 肿瘤学
  • 创伤治疗
  • 其他用途

第九章 全球再生医学技术市场：依最终用户划分

  • 医院
  • 专科诊所
  • 研究机构
  • 生技公司
  • 製药公司
  • 学术机构
  • 其他最终用户

第十章 全球再生医学技术市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十一章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十二章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十三章：公司简介

  • Astellas Pharma Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Johnson & Johnson
  • Vericel Corporation
  • Mesoblast Limited
  • Organogenesis Holdings Inc.
  • Bluebird Bio, Inc.
  • Sangamo Therapeutics
  • CRISPR Therapeutics AG
  • Editas Medicine
  • Intellia Therapeutics
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Amgen Inc.
Product Code: SMRC34767

According to Stratistics MRC, the Global Regenerative Medicine Technologies Market is accounted for $18.4 billion in 2026 and is expected to reach $78.2 billion by 2034 growing at a CAGR of 19.8% during the forecast period. Regenerative medicine technologies refer to a multidisciplinary field of biomedical science focused on restoring, replacing, or regenerating damaged tissues and organs through harnessing biological mechanisms of repair and self-renewal. They encompass stem cell therapies, gene therapy vectors, tissue engineering constructs, biomaterial scaffolds, and cell-based immunotherapies. These technologies utilize autologous, allogeneic, and xenogeneic cellular sources combined with bioprocessing platforms, 3D bioprinting systems, and CRISPR-based gene editing tools to address orthopedic, cardiac, neurological, dermatological, and oncological indications.

Market Dynamics:

Driver:

Gene Therapy Regulatory Approvals

Gene therapy regulatory approvals are accelerating regenerative medicine market expansion as landmark FDA and EMA clearances for hereditary disease treatments validate the commercial and clinical viability of advanced cellular and genetic therapies. Approval of multiple gene therapies for rare disorders has established market pricing precedents and demonstrated willingness-to-pay dynamics that are attracting substantial investment into broader regenerative technology pipelines. Manufacturing capability scaling supported by approved products is additionally reducing per-unit costs and improving technology accessibility for wider patient populations.

Restraint:

Complex Manufacturing and Scaling Challenges

Complex biomanufacturing requirements and scaling challenges represent the most significant operational barrier facing regenerative medicine technology commercialization. Autologous cell therapy manufacturing requires individualized patient-specific production runs that are difficult to standardize, creating high per-dose costs incompatible with broad healthcare system economics. Allogeneic platform development mitigates some scaling constraints but introduces immunogenicity management complexity. Contamination risks and sterility maintenance requirements across cell expansion, formulation, and distribution workflows impose substantial GMP compliance investment.

Opportunity:

Orthopedic Regeneration Applications

Orthopedic regeneration applications represent a high-volume commercial opportunity as aging global populations experience rising musculoskeletal disorder prevalence that regenerative interventions can address more effectively than current surgical and pharmaceutical options. Cartilage repair, bone regeneration, and tendon healing applications using biomaterial scaffolds and growth factor delivery platforms are progressing through regulatory pathways. Orthopedic surgeon adoption of regenerative adjuncts within established surgical workflows is generating early commercial traction with attractive procedure economics and reimbursement comparability to existing standard interventions.

Threat:

Pricing and Reimbursement Sustainability Challenges

Pricing and reimbursement sustainability challenges pose a systemic commercial threat to regenerative medicine technology developers, as single-administration curative therapies with transformative clinical outcomes require novel payment models that traditional annual insurance premium and capitation structures cannot accommodate. Value-based payment frameworks, annuity-style reimbursement schemes, and outcomes-linked payment mechanisms are under active negotiation with payers but lack standardized implementation frameworks. Health technology assessment bodies are applying exceptional scrutiny to regenerative therapy pricing submissions, extending market access timelines.

Covid-19 Impact:

COVID-19 disrupted regenerative medicine clinical trial timelines through site closures and patient enrollment suspensions, delaying several late-stage programs by one to two years. However, pandemic mRNA technology investments accelerated delivery platform innovations applicable to regenerative gene therapy vectors. Post-pandemic regulatory agencies and manufacturers collaborated on clinical trial resilience frameworks that have structurally improved program continuity planning.

The scaffold technologies segment is expected to be the largest during the forecast period

The scaffold technologies segment is expected to account for the largest market share during the forecast period, due to broad clinical utility across tissue engineering applications in orthopedics, wound healing, and cardiac repair, combined with relatively well-established manufacturing and regulatory approval infrastructure. Biocompatible scaffold materials including hydrogels, bioceramics, and biodegradable polymers have achieved commercial traction in multiple approved medical device products. Growing 3D bioprinting integration with scaffold design is enabling patient-specific anatomical geometry customization, expanding clinical application scope.

The autologous cells segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the autologous cells segment is predicted to witness the highest growth rate, driven by escalating CAR-T cell therapy commercial penetration across hematological malignancies, expanding autologous chondrocyte implantation for cartilage repair, and growing autologous stem cell transplantation for hematopoietic reconstitution. Regulatory approval momentum for autologous cell-based therapies is compounding, with multiple programs in Phase III generating positive efficacy data. Manufacturing automation investments are progressively reducing autologous cell therapy production costs.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to concentration of approved cell and gene therapy products, leading academic medical research infrastructure, and substantial private and government investment in regenerative medicine technology development. The U.S. FDA's Center for Biologics Evaluation and Research has established robust regulatory pathways supporting cell and gene therapy commercialization. Key companies including Bristol-Myers Squibb Company and Gilead Sciences, Inc. maintain leading commercial CAR-T therapy market positions.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to Japan's innovative SAKIGAKE designation providing expedited regenerative medicine approvals, South Korea's active cell therapy regulatory framework, and China's massive investment in domestic stem cell therapy development programs. Government funding for national regenerative medicine centers across Asia Pacific is creating clinical trial infrastructure that is attracting global technology partnership opportunities and accelerating regional commercial launches.

Key players in the market

Some of the key players in Regenerative Medicine Technologies Market include Astellas Pharma Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Johnson & Johnson, Vericel Corporation, Mesoblast Limited, Organogenesis Holdings Inc., Bluebird Bio, Inc., Sangamo Therapeutics, CRISPR Therapeutics AG, Editas Medicine, Intellia Therapeutics, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences, Inc., and Amgen Inc..

Key Developments:

In March 2026, Organogenesis Holdings Inc. received CMS reimbursement expansion for its regenerative wound care biomaterial platform across additional chronic wound indication categories.

In February 2026, Mesoblast Limited secured regulatory approval in Australia for its allogeneic mesenchymal stem cell therapy targeting treatment-refractory pediatric graft-versus-host disease.

In January 2026, CRISPR Therapeutics AG initiated pivotal trial enrollment for its next-generation gene-edited autologous T-cell therapy targeting aggressive relapsed/refractory B-cell malignancies.

In November 2025, Intellia Therapeutics reported transformative Phase II gene editing therapy data demonstrating durable disease modification in patients with hereditary transthyretin amyloidosis.

Product Types Covered:

  • Stem Cell Therapy
  • Tissue Engineering
  • Gene Therapy
  • Biomaterials
  • Scaffold Technologies
  • Cell-based Immunotherapy
  • Other Product Types

Sources Covered:

  • Autologous Cells
  • Allogeneic Cells
  • Xenogeneic Cells
  • Embryonic Stem Cells
  • Adult Stem Cells
  • Induced Pluripotent Stem Cells
  • Other Sources

Technologies Covered:

  • 3D Bioprinting
  • CRISPR Gene Editing
  • Cell Reprogramming
  • Nanotechnology
  • Bioprocessing Technologies
  • Bioreactors

Applications Covered:

  • Orthopedics
  • Cardiology
  • Neurology
  • Dermatology
  • Oncology
  • Wound Healing
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Regenerative Medicine Technologies Market, By Product Type

  • 5.1 Stem Cell Therapy
  • 5.2 Tissue Engineering
  • 5.3 Gene Therapy
  • 5.4 Biomaterials
  • 5.5 Scaffold Technologies
  • 5.6 Cell-based Immunotherapy
  • 5.7 Other Product Types

6 Global Regenerative Medicine Technologies Market, By Source

  • 6.1 Autologous Cells
  • 6.2 Allogeneic Cells
  • 6.3 Xenogeneic Cells
  • 6.4 Embryonic Stem Cells
  • 6.5 Adult Stem Cells
  • 6.6 Induced Pluripotent Stem Cells
  • 6.7 Other Sources

7 Global Regenerative Medicine Technologies Market, By Technology

  • 7.1 3D Bioprinting
  • 7.2 CRISPR Gene Editing
  • 7.3 Cell Reprogramming
  • 7.4 Nanotechnology
  • 7.5 Bioprocessing Technologies
  • 7.6 Bioreactors

8 Global Regenerative Medicine Technologies Market, By Application

  • 8.1 Orthopedics
  • 8.2 Cardiology
  • 8.3 Neurology
  • 8.4 Dermatology
  • 8.5 Oncology
  • 8.6 Wound Healing
  • 8.7 Other Applications

9 Global Regenerative Medicine Technologies Market, By End User

  • 9.1 Hospitals
  • 9.2 Specialty Clinics
  • 9.3 Research Institutes
  • 9.4 Biotechnology Companies
  • 9.5 Pharmaceutical Companies
  • 9.6 Academic Institutes
  • 9.7 Other End Users

10 Global Regenerative Medicine Technologies Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Astellas Pharma Inc.
  • 13.2 Novartis AG
  • 13.3 Pfizer Inc.
  • 13.4 Roche Holding AG
  • 13.5 Johnson & Johnson
  • 13.6 Vericel Corporation
  • 13.7 Mesoblast Limited
  • 13.8 Organogenesis Holdings Inc.
  • 13.9 Bluebird Bio, Inc.
  • 13.10 Sangamo Therapeutics
  • 13.11 CRISPR Therapeutics AG
  • 13.12 Editas Medicine
  • 13.13 Intellia Therapeutics
  • 13.14 Takeda Pharmaceutical Company Limited
  • 13.15 Bristol-Myers Squibb Company
  • 13.16 AbbVie Inc.
  • 13.17 Gilead Sciences, Inc.
  • 13.18 Amgen Inc.

List of Tables

  • Table 1 Global Regenerative Medicine Technologies Market Outlook, By Region (2023-2034)($MN)
  • Table 2 Global Regenerative Medicine Technologies Market Outlook, By Product Type (2023-2034)($MN)
  • Table 3 Global Regenerative Medicine Technologies Market Outlook, By Stem Cell Therapy (2023-2034)($MN)
  • Table 4 Global Regenerative Medicine Technologies Market Outlook, By Tissue Engineering (2023-2034)($MN)
  • Table 5 Global Regenerative Medicine Technologies Market Outlook, By Gene Therapy (2023-2034)($MN)
  • Table 6 Global Regenerative Medicine Technologies Market Outlook, By Biomaterials (2023-2034)($MN)
  • Table 7 Global Regenerative Medicine Technologies Market Outlook, By Scaffold Technologies (2023-2034)($MN)
  • Table 8 Global Regenerative Medicine Technologies Market Outlook, By Cell-based Immunotherapy (2023-2034)($MN)
  • Table 9 Global Regenerative Medicine Technologies Market Outlook, By Other Product Types (2023-2034)($MN)
  • Table 10 Global Regenerative Medicine Technologies Market Outlook, By Source (2023-2034)($MN)
  • Table 11 Global Regenerative Medicine Technologies Market Outlook, By Autologous Cells (2023-2034)($MN)
  • Table 12 Global Regenerative Medicine Technologies Market Outlook, By Allogeneic Cells (2023-2034)($MN)
  • Table 13 Global Regenerative Medicine Technologies Market Outlook, By Xenogeneic Cells (2023-2034)($MN)
  • Table 14 Global Regenerative Medicine Technologies Market Outlook, By Embryonic Stem Cells (2023-2034)($MN)
  • Table 15 Global Regenerative Medicine Technologies Market Outlook, By Adult Stem Cells (2023-2034)($MN)
  • Table 16 Global Regenerative Medicine Technologies Market Outlook, By Induced Pluripotent Stem Cells (2023-2034)($MN)
  • Table 17 Global Regenerative Medicine Technologies Market Outlook, By Other Sources (2023-2034)($MN)
  • Table 18 Global Regenerative Medicine Technologies Market Outlook, By Technology (2023-2034)($MN)
  • Table 19 Global Regenerative Medicine Technologies Market Outlook, By 3D Bioprinting (2023-2034)($MN)
  • Table 20 Global Regenerative Medicine Technologies Market Outlook, By CRISPR Gene Editing (2023-2034)($MN)
  • Table 21 Global Regenerative Medicine Technologies Market Outlook, By Cell Reprogramming (2023-2034)($MN)
  • Table 22 Global Regenerative Medicine Technologies Market Outlook, By Nanotechnology (2023-2034)($MN)
  • Table 23 Global Regenerative Medicine Technologies Market Outlook, By Bioprocessing Technologies (2023-2034)($MN)
  • Table 24 Global Regenerative Medicine Technologies Market Outlook, By Bioreactors (2023-2034)($MN)
  • Table 25 Global Regenerative Medicine Technologies Market Outlook, By Application (2023-2034)($MN)
  • Table 26 Global Regenerative Medicine Technologies Market Outlook, By Orthopedics (2023-2034)($MN)
  • Table 27 Global Regenerative Medicine Technologies Market Outlook, By Cardiology (2023-2034)($MN)
  • Table 28 Global Regenerative Medicine Technologies Market Outlook, By Neurology (2023-2034)($MN)
  • Table 29 Global Regenerative Medicine Technologies Market Outlook, By Dermatology (2023-2034)($MN)
  • Table 30 Global Regenerative Medicine Technologies Market Outlook, By Oncology (2023-2034)($MN)
  • Table 31 Global Regenerative Medicine Technologies Market Outlook, By Wound Healing (2023-2034)($MN)
  • Table 32 Global Regenerative Medicine Technologies Market Outlook, By Other Applications (2023-2034)($MN)
  • Table 33 Global Regenerative Medicine Technologies Market Outlook, By End User (2023-2034)($MN)
  • Table 34 Global Regenerative Medicine Technologies Market Outlook, By Hospitals (2023-2034)($MN)
  • Table 35 Global Regenerative Medicine Technologies Market Outlook, By Specialty Clinics (2023-2034)($MN)
  • Table 36 Global Regenerative Medicine Technologies Market Outlook, By Research Institutes (2023-2034)($MN)
  • Table 37 Global Regenerative Medicine Technologies Market Outlook, By Biotechnology Companies (2023-2034)($MN)
  • Table 38 Global Regenerative Medicine Technologies Market Outlook, By Pharmaceutical Companies (2023-2034)($MN)
  • Table 39 Global Regenerative Medicine Technologies Market Outlook, By Academic Institutes (2023-2034)($MN)
  • Table 40 Global Regenerative Medicine Technologies Market Outlook, By Other End Users (2023-2034)($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.